Montelucaste Tecnilor (Montelukast)

Montelukast, the active ingredient in Montelucaste Tecnilor, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in both adult and pediatric patients.

GNH USA supplies Montelucaste Tecnilor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards, is manufactured under strict GMP conditions, and our distribution network ensures timely delivery across multiple regions.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation.

- Asthma: improves control of chronic symptoms and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: transient irritation of the throat or airways. - Fever: low‑grade temperature elevation without infection.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression, suicidal thoughts, or hallucinations. - Allergic reactions: rash, urticaria, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Montelucaste Tecnilor, clinicians should consider several safety aspects.

- Assess liver function: evaluate hepatic status, especially in patients with known liver disease. - Monitor neuropsychiatric symptoms: watch for mood changes, depression, or suicidal ideation. - Use with caution in severe hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to montelukast or any excipients. - Pregnancy: consult a healthcare professional before use; benefits must outweigh potential risks. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may markedly reduce montelukast plasma concentrations. - Rifampin: strong CYP3A inducer that can lower drug exposure. - Ketoconazole: potent CYP3A inhibitor may increase montelukast levels.

Moderate Interactions (Monitor Closely): - Aspirin and NSAIDs: may increase risk of bronchospasm in sensitive individuals. - Warfarin: monitor INR as montelukast could alter anticoagulant effect. - Beta‑agonists: additive bronchodilatory effect may require clinical observation.